Métadonnées
Afficher la notice complètePartager cette publication !
Complete loss of function of the ubiquitin ligase HERC2 causes a severe neurodevelopmental phenotype.
MORICE-PICARD, Fanny
Service de génétique médicale
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
CHU de Bordeaux Pellegrin [Bordeaux]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
Service de génétique médicale
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
CHU de Bordeaux Pellegrin [Bordeaux]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
BENARD, Giovanni
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
REZVANI, Hamid Reza
Biothérapies des maladies génétiques et cancers
BoRdeaux Institute in onCology [Inserm U1312 - BRIC]
Voir plus >
Biothérapies des maladies génétiques et cancers
BoRdeaux Institute in onCology [Inserm U1312 - BRIC]
MORICE-PICARD, Fanny
Service de génétique médicale
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
CHU de Bordeaux Pellegrin [Bordeaux]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
Service de génétique médicale
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
CHU de Bordeaux Pellegrin [Bordeaux]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
BENARD, Giovanni
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
REZVANI, Hamid Reza
Biothérapies des maladies génétiques et cancers
BoRdeaux Institute in onCology [Inserm U1312 - BRIC]
Biothérapies des maladies génétiques et cancers
BoRdeaux Institute in onCology [Inserm U1312 - BRIC]
MOUTTON, Sébastien
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
ROORYCK, Caroline
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
LACOMBE, Didier
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
CHU de Bordeaux Pellegrin [Bordeaux]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
CHU de Bordeaux Pellegrin [Bordeaux]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
ARVEILER, Benoit
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
< Réduire
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
Langue
EN
Article de revue
Ce document a été publié dans
European Journal of Human Genetics. 2016-01-01, vol. 25, n° 1, p. 52-58
Résumé en anglais
The ubiquitin-proteasome pathway is involved in the pathogenesis of several neurogenetic diseases. We describe a Mauritanian patient harboring a homozygous deletion restricted to two contiguous genes HERC2 and OCA2 and ...Lire la suite >
The ubiquitin-proteasome pathway is involved in the pathogenesis of several neurogenetic diseases. We describe a Mauritanian patient harboring a homozygous deletion restricted to two contiguous genes HERC2 and OCA2 and presenting with severe developmental abnormalities. The deletion causes the complete loss of HERC2 protein function, an E3-ubiquitin ligase. HERC2 is known to target XPA and BRCA1 for degradation and a mechanism whereby it is involved in DNA repair and cell cycle regulation. We showed that loss of HERC2 function leads to the accumulation of XPA and BRCA1 in the patient's fibroblasts and generates decreased sensitivity to apoptosis and increased level of DNA repair. Our data describe for the first time the phenotypic consequences, both at the clinical and cellular levels, of a complete loss of HERC2 function in a patient. They strongly suggest that profound ubiquitin ligase - associated dysfunction is responsible for the severe phenotype in this patient, and that dysfunction of this pathway may be involved in other patients with similar neurodevelopmental diseases.< Réduire
Unités de recherche